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Blood circulationBackground: Chronic supplementation with L-citrulline plus L-arginine has been shown to exhibit anti-
atherosclerotic effects. However, the short-term action of this combination on the nitric oxide (NO)–
cGMP pathway remains to be elucidated. The objective of the present study was to investigate the acute
effects of a combination of oral L-citrulline and L-arginine on plasma L-arginine and NO levels, as well as
on blood circulation.
Methods: Rats or New Zealand white rabbits were treated orally with L-citrulline, or L-arginine, or a com-
bination of each at half dosage. Following supplementation, plasma levels of L-arginine, NOx, cGMP and
changes in blood circulation were determined sequentially.
Results: L-Citrulline plus L-arginine supplementation caused a more rapid increase in plasma L-arginine
levels and marked enhancement of NO bioavailability, including plasma cGMP concentrations, than with
dosage with the single amino acids. Blood ﬂow in the central ear artery in rabbits was also signiﬁcantly
increased by L-citrulline plus L-arginine administration as compared with the control.
Conclusion: Our data show for the ﬁrst time that a combination of oral L-citrulline and L-arginine effec-
tively and rapidly augments NO-dependent responses at the acute stage. This approach may have clinical
utility for the regulation of cardiovascular function in humans.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Nitric oxide (NO) is a widespread signaling molecule in the car-
diovascular system as well as in various cell types, and also pro-
tects in multiple ways against the initiation and progression of
atherosclerosis [1,2]. NO produced from L-arginine by endothelial
NO synthase (eNOS) plays an important role in regulating endothe-
lium-dependent vasodilatation [1–3], preventing the adhesion of
blood cells and platelets along the endothelial cell layer of blood
vessels [4], and inhibiting vascular smooth muscle cell prolifera-
tion [5]. NO also shows scavenging effects against oxygen radical
species, including the prevention of oxidation of LDL-cholesterol
[6]. Thus, reduced NO bioavailability caused by endothelial impair-ment is associated with atherosclerotic coronary artery disease
[7,8].
To augment NO-dependent responses, oral treatment with L-
arginine of animals [9–11] and humans [12–14] has been studied
extensively, with the aim of suppressing the progression of athero-
sclerosis or its component processes by restoring physiological lev-
els of NO. One of the principal explanations of the therapeutic
function of L-arginine is increased availability of substrate for
eNOS, for example, by competing with asymmetric dimethylargi-
nine which is elevated in states of atherosclerosis as an endoge-
nous competitive inhibitor of eNOS [15]. However, relatively
large doses of 5–15 g/day would be required to improve endothe-
lial function in humans.
L-Citrulline is a colorless, water-soluble a-amino acid that is a
potent endogenous precursor of L-arginine. In a recent clinical
study, L-citrulline supplementation dose-dependently increases
plasma L-arginine levels in healthy human volunteers more effec-
tively than equivalent doses of L-arginine itself [16]. Furthermore,
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L-citrulline supplementation functionally improves arterial stiff-
ness [17], decreases the state of lipoprotein oxidation [18], reduces
ankle blood pressure and carotid wave reﬂection [19], and causes a
reduction in the heart rate-corrected QT interval as a marker of
sudden cardiac death [20]. Thus, L-citrulline supplementation has
been shown to exhibit several beneﬁcial effects on the cardiovas-
cular system.
In the present study, we focused on a potential strategy for pro-
moting the L-citrulline-to-L-arginine recycling pathway, which is
the principal mechanism for sustaining localized L-arginine avail-
ability for eNOS-catalyzed NO production, by simultaneous appli-
cation of L-citrulline and L-arginine. Our previous study revealed
that chronic administration of a combination of L-citrulline and L-
arginine has a better therapeutic effect on high-cholesterol
induced atherosclerosis in rabbits [21]. However, the short-term
actions of this combination have as yet not been investigated.
Therefore, the purpose of this study was to evaluate the acute
effects of simultaneous administration with L-citrulline plus L-argi-
nine on plasma L-arginine, NO bioavailability and blood circulation
associated with the NO-cGMP pathway.
2. Methods
2.1. Animals
Animal studies were conducted in accordance with the guide-
lines for the Institutional Animal Care and Use Committee of
Nagoya University and KYOWA HAKKO BIO CO., LTD.
Fifteen male Sprague–Dawley rats (9 weeks old; Japan SLC Inc.,
Hamamatsu, Japan) were given free access to standard rat chow
(CE-2, CLEA JAPAN Inc., Tokyo, Japan) and tap water in a room with
controlled temperature (22 ± 2 C), humidity (55 ± 5 C) and a 12-h
light/dark cycle. After the rats had been anesthetized with pento-
barbital sodium (30 mg/kg, i.p.), a catheter was inserted into the
jugular vein. Following three days of acclimation, the rats were
used for the following experiments.
Nine male New Zealand White rabbits (8 weeks old; Kitayama
Labes Co., Ltd., Nagano, Japan) were housed individually in a room
with controlled temperature (20 ± 3 C) and free access to water.
Feeding of standard feed was limited to 120 g per day per rabbit.
2.2. Experimental designs
After a 16-h fast, the rats and the rabbits were each randomly
assigned to three separate groups respectively, and received single
oral gavage of either L-citrulline (2.85 mmol/kg), L-arginine
(2.85 mmol/kg) or a combination of each at half dosage
(1.43 mmol/kg). L-citrulline and L-arginine were obtained from0 
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Fig. 1. Time course of changes in plasma L-arginine concentrations. Rabbits (A) or rats (B)
half dosage (4) by oral gavage. Blood samples were collected sequentially before and aft
as mean with SD. Signiﬁcant difference from the L-citrulline group (⁄p < 0.05), or the L-cKYOWA HAKKO BIO CO., LTD. (Tokyo, Japan). Blood samples were
collected from the catheter (rats) or the ear vein (rabbits) at 0
(pre-value), 0.5, 1, 2, and 4 h after the administration. We used
the rat plasma for analyzing L-arginine levels only, and the rabbit
plasma for all the measurements. The blood ﬂow level in the cen-
tral ear artery in rabbits was measured at 40 min after
supplementation.
2.3. Measurements of plasma L-arginine, NOx and cGMP
Blood samples were collected into heparinized tubes for L-argi-
nine assay, or vacuum tubes containing sodium EDTA for NOx
(nitrite plus nitrate) and cGMP. They were immediately centri-
fuged to obtain the supernatant. Analytical procedures and meth-
ods were basically the same as described previously. Brieﬂy, the
concentration of L-arginine in plasma was determined using an
amino acid analyzer (JLC-500/V; JEOL, Tokyo, Japan) [22]. Plasma
NOx was measured using an NO detector-HPLC system (ENO10;
Eicom, Kyoto, Japan) as described [23]. Plasma cGMP concentration
was determined by speciﬁc radioimmunoassay (RPN226, Amer-
sham, Buckinghamshire, England) [24].
2.4. Determination of tissue blood ﬂow
To measure the blood ﬂow in a 3 cm-length from the proximal
region of the right central ear artery, we used a laser Doppler imag-
ing system (LDPI: Laser Doppler Perfusion Imager PIMII, PERIMED
AB, Linköping, Sweden), as we reported previously [21]. This
method provides 2-dimensional mapping of blood ﬂow in tissue
and is based on the principles of laser Doppler ﬂowmetry. Rabbits
treated orally with puriﬁed water were used as controls.
2.5. Data analysis
Results were expressed as mean ± SD, and represent unpaired
data. Following a comparison of the data by non-repeated analysis
of variance (ANOVA), the Bonferroni correction for multiple tests or
Scheffe’s test for multiple comparisons was used to identify the dif-
ferences among treatments. A p-value of less than 0.05 was consid-
ered to be statistically signiﬁcant. Statistical analysis was
performed using Statcel software for Windows (Version 2, OMS
Publishing, Inc., Saitama, Japan) and the ystat 2000 Statistical Pro-
gram File (Igaku Tosho Shuppan, Tokyo, Japan).
3. Results
Fig. 1 shows the time-course of changes in plasma L-arginine
concentrations. Compared with the single amino acid, simulta-
neous administration with L-citrulline and L-arginine to rabbits0 
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were administered either L-citrulline (h), L-arginine (s) or a combination of each at
er administration to analyze plasma L-arginine concentrations. Values are expressed
itrulline group, L-arginine group (p < 0.05). n = 3 (A), n = 5 (B).
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Fig. 2. Time course of changes in plasma NOx (A) and cGMP (B) concentrations. Rabbits were administered either L-citrulline (h), L-arginine (s) or a combination of each at
half dosage (4) by oral gavage. Blood samples were collected sequentially before and after administration to analyze plasma NOx and cGMP concentrations. Values are
expressed as mean with SD. Signiﬁcant difference from L-citrulline group, L-arginine group (⁄p < 0.05), or L-arginine group (#p < 0.05). n = 3.
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Fig. 3. Blood ﬂow levels in the central ear artery after administration. Rabbits were
administered either L-citrulline, L-arginine or a combination of each at half dosage
by oral gavage. Blood ﬂow in the central ear artery was measured at 40 min after
administration. Values are expressed as mean with SD. Signiﬁcant difference from
control group (⁄p < 0.05). n = 3.
M. Morita et al. / Biochemical and Biophysical Research Communications 454 (2014) 53–57 55rapidly raised plasma L-arginine levels, with time to reach peak
concentration of less than an hour after supplementation
(Fig. 1A). This rapid kinetics in plasma L-arginine was corroborated
and reappeared clearly in healthy rats (Fig. 1B).
Fig. 2 shows the time-course of changes in plasma NOx and
cGMP concentrations. We observed an approximately twofold
increase in plasma NOx levels after L-citrulline or L-arginine admin-
istration as compared with 0 h (pre-value). Furthermore, a combi-
nation of each at half dosage caused a signiﬁcantly greater increase
in NOx levels than a single amino acid (Fig. 2A). Plasma levels of
cGMP, an important signaling molecule in the vasodilative path-
way, also increased more rapidly in the 1 h following simultaneous
administration with L-citrulline plus L-arginine when compared
with a single amino acid (Fig. 2B).
The blood ﬂow levels in the central ear artery at 40 min follow-
ing supplementation are given in Fig. 3. Compared with the con-
trol, L-citrulline or L-arginine supplementation tends to increase
blood ﬂow, but not statistically signiﬁcant. In contrast, simulta-
neous administration with both at half dosage results in a signiﬁ-
cant enhancement in the blood ﬂow level as compared with the
control.4. Discussion
The primary objective of the present study was to determine
the short-term action of oral L-citrulline plus L-arginine on plasma
parameters for the NO-cGMP pathway. This is the ﬁrst study on therapid kinetics of plasma L-arginine, NOx and cGMP levels after
simultaneous administration in comparison with the single amino
acids. The major ﬁndings of our study are that a combination of
oral L-citrulline and L-arginine effectively and rapidly increases
plasma L-arginine and augments NO-dependent responses, partic-
ularly within 1 h after supplementation.
NO, the endothelium-derived vasoactive factor, is produced
from L-arginine by eNOS via the L-citrulline/L-arginine recycling
pathway [1–3]. To investigate the effects of L-arginine, the sub-
strate for NO synthesis, many researchers have carried out studies
on vascular function. It has been reported that intervention with L-
arginine can improve endothelial dysfunction in humans and ani-
mal models [9,10,12–14,25]. However, the recent literature has
reported no effects of chronic administration of L-arginine [26–
28], because orally administered L-arginine is strongly trapped in
the gastrointestinal tract and the hepatic tissue, where it is exten-
sively catabolized by arginase [27,29], suggesting it to have limited
oral bioavailability as a substrate for eNOS. On the other hand, sev-
eral studies have persuasively demonstrated that L-citrulline is an
effective precursor of L-arginine, thus contributing to sustained L-
arginine supply for eNOS activity [16,18,22]. As a noteworthy ﬁnd-
ing in this study, a rapid increase in plasma L-arginine levels was
observed with a combination of oral L-citrulline plus L-arginine
than for a single amino acid. Interestingly, previous researches
in vitro and in vivo have demonstrated that L-citrulline suppresses
arginase activity, acting as a strong allosteric inhibitor [30], and
exerts an anti-hypertensive effect in animals via a mechanism
involving arginase inhibition by L-citrulline [31]. This could provide
one possible mechanism for the rapid and signiﬁcant increase in
plasma L-arginine levels, suggesting that L-arginine could pass
through the gastrointestinal tract and liver without being inﬂu-
enced by intestinal and hepatic-ﬁrst pass effects, probably due to
inhibition of arginase activity by L-citrulline (Fig. 4). These ﬁndings
suggest the role played by L-citrulline in upregulating L-arginine
bioavailability, leading to enhancement of the NO-cGMP pathway.
Upregulation of the L-citrulline/L-arginine recycling pathway
and increased eNOS expression are accompanied by increased
plasma NOx and cGMP. Here, the intracellular L-arginine concentra-
tion is sufﬁcient level for the km (2–15 lM) for L-arginine as a sub-
strate for eNOS [27,32]. However, a previous report suggests that
intracellular endothelial L-arginine may not in fact be available
for NO production, since cytosolic L-arginine availability for eNOS
may be limited by its sequestration in the plasmalemmal caveolae
in which the eNOS and the L-citrulline to L-arginine recycling path-
way are localized [33]. Moreover, recent study has suggested one
possible mechanism in which the principal source of available L-
arginine for NO production is uptake from extracellular, not cyto-
solic L-arginine [34]. These observations support the notion that a
combination of L-citrulline plus L-arginine effectively increases
L-Citrulline
(allosteric inhibitor)
Arginase
L-Arginine
L-Ornithine
Gastrointestinal tract
(allosteric inhibitor)
Arginase
L-Ornithine
Hepatic tissue
Rapid increase of L-arginine 
in peripheral circulation
L-Citrulline
L-Arginine
Kidney
Vascular endothelium
NO-cGMP 
pathway
First-pass effect for L-arginine
Fig. 4. A proposed mechanism for simultaneous administration with L-citrulline plus L-arginine leading to rapid raising of plasma L-arginine levels.
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the present study clearly indicate L-arginine-linked enhancement
of plasma NOx and cGMP levels following simultaneous adminis-
tration with L-citrulline and L-arginine.
Interestingly, marked increases in plasma NOx and cGMP levels
were observed after L-citrulline supplementation, although the
rises in plasma L-arginine after L-citrulline supplementation were
a slight change in rabbits. It has been indicated that L-citrulline
added to cultured endothelial cells sustains NOS activity and NO
production under L-arginine-deﬁcient conditions [27]. L-Citrulline
itself can also be transported into endothelial cells by the neural
amino acid system N transporter 1 (SN1) [35]. We therefore spec-
ulate that direct uptake of L-citrulline into the endothelial cells
may provide a substrate for the formation of L-arginine via L-citrul-
line/L-arginine recycling pathway and contribute to upregulation
of eNOS activity.
Here, time to reach peak concentration (Tmax) of plasma L-argi-
nine after oral L-citrulline is approximately 2 h in humans [16] and
4 h in animals (our unpublished data), which suggests that the
combination of L-citrulline plus L-arginine is useful for short-acting
effects, as shown in the present study, while L-citrulline alone is
useful for long-acting enhancement of L-arginine availability.
Indeed, this suggestion is further supported by our ﬁnding that L-
citrulline administration to rats signiﬁcantly increases the area
under the concentration–time curve (AUC0–12h) to a greater extent
than L-arginine itself (data not shown).
Our previous study revealed that long-term L-citrulline plus L-
arginine supplementation causes a signiﬁcant improvement in
endothelium-dependent vasorelaxation and dramatic regression
in atheromatous lesions in experimentally-induced atherosclerosis
in rabbits [21]. As one possible mechanism, we have also shown
increased expression of eNOS protein by combination of these
two amino acids [21]. However, the short-term action of the com-
bination of L-citrulline plus L-arginine on the NO-cGMP pathway
remains to be elucidated. Thus, our corroborative ﬁndings in this
study propose a potentially novel strategy for rapidly potentiating
NO-cGMP dependent reactions in the short-term, which is capable
of increasing plasma L-arginine and NOx levels, as well as blood cir-
culation rapidly and effectively, likely due to upregulation of the L-
citrulline/L-arginine recycling pathway and eNOS expression.
Growing evidences suggest endothelial dysfunction, which is
strongly associated with reduced NO bioavailability, to be an initi-
ating factor in cardiovascular diseases [7,8,36]. Our data suggests
the clinical beneﬁt on vascular function of L-citrulline plus L-argi-
nine supplementation. However, we believe a further study in
humans is needed to be able to present a therapeutic option with
clinical utility.
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